Chemed Corporation (NYSE:CHE) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Chemed Corporation (NYSE:CHE) have earned an average recommendation of “Moderate Buy” from the six research firms that are covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $574.25.

A number of research analysts have recently commented on the stock. Royal Bank Of Canada dropped their price objective on shares of Chemed from $589.00 to $572.00 and set an “outperform” rating for the company in a research note on Monday, November 10th. Zacks Research raised shares of Chemed from a “strong sell” rating to a “hold” rating in a research report on Thursday, October 30th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Chemed in a research note on Wednesday, October 8th.

Chemed Stock Down 1.1%

CHE stock opened at $444.30 on Friday. Chemed has a 52-week low of $408.42 and a 52-week high of $623.60. The stock’s fifty day simple moving average is $434.16 and its 200-day simple moving average is $446.69. The stock has a market capitalization of $6.29 billion, a price-to-earnings ratio of 23.50, a price-to-earnings-growth ratio of 2.16 and a beta of 0.44.

Chemed (NYSE:CHE) last released its earnings results on Tuesday, October 28th. The company reported $5.27 EPS for the quarter, missing the consensus estimate of $5.39 by ($0.12). Chemed had a net margin of 11.02% and a return on equity of 25.89%. The business had revenue of $624.90 million during the quarter, compared to analyst estimates of $626.04 million. During the same quarter in the previous year, the company posted $5.64 earnings per share. The business’s revenue for the quarter was up 3.1% compared to the same quarter last year. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. As a group, analysts anticipate that Chemed will post 21.43 earnings per share for the current fiscal year.

Chemed Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, December 5th. Investors of record on Monday, November 17th were issued a $0.60 dividend. The ex-dividend date was Monday, November 17th. This represents a $2.40 dividend on an annualized basis and a yield of 0.5%. Chemed’s dividend payout ratio (DPR) is presently 12.69%.

Insider Buying and Selling

In other Chemed news, CEO Kevin J. Mcnamara sold 2,000 shares of the company’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $437.55, for a total transaction of $875,100.00. Following the completion of the sale, the chief executive officer directly owned 94,197 shares in the company, valued at $41,215,897.35. This represents a 2.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 3.29% of the stock is owned by corporate insiders.

Institutional Trading of Chemed

A number of institutional investors have recently modified their holdings of the company. Vontobel Holding Ltd. boosted its position in Chemed by 44.5% during the 2nd quarter. Vontobel Holding Ltd. now owns 2,821 shares of the company’s stock worth $1,374,000 after purchasing an additional 869 shares during the period. Sequoia Financial Advisors LLC purchased a new position in Chemed in the second quarter valued at about $342,000. Signal Advisors Wealth LLC lifted its stake in shares of Chemed by 49.5% during the second quarter. Signal Advisors Wealth LLC now owns 9,586 shares of the company’s stock worth $4,667,000 after purchasing an additional 3,174 shares in the last quarter. Covea Finance boosted its position in shares of Chemed by 52.3% in the second quarter. Covea Finance now owns 9,900 shares of the company’s stock worth $4,821,000 after buying an additional 3,400 shares during the period. Finally, Fenimore Asset Management Inc grew its stake in shares of Chemed by 28.3% in the third quarter. Fenimore Asset Management Inc now owns 37,240 shares of the company’s stock valued at $16,674,000 after buying an additional 8,222 shares in the last quarter. Hedge funds and other institutional investors own 95.85% of the company’s stock.

About Chemed

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.